Tagrisso Approved as First Adjuvant Treatment of EGFR-Mutated NSCLC
The FDA approved osimertinib (Tagrisso, AstraZeneca) for adjuvant therapy after tumor resection in adults with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.